Futuremedicine

FutureMedicine is a South Korean clinical-stage biotechnology company focused on developing innovative small molecule therapeutics using its proprietary nucleoside-based drug discovery platform. The company primarily targets adenosine receptors to treat inflammatory, fibrotic, and metabolic diseases, as well as cancer. Its lead candidate, FM101, is a selective adenosine A3 receptor antagonist currently in Phase 2 clinical trials for non-alcoholic steatohepatitis (NASH) and glaucoma. FutureMedicine's pipeline also includes programs for chronic kidney disease and immuno-oncology. By leveraging its expertise in medicinal chemistry, the company seeks to provide first-in-class treatments for conditions with high unmet medical needs. The company is listed on the KONEX exchange and continues to advance its candidates through global clinical development.